Synergistic inhibitory effect of Smo inhibitor jervine and its combination with decitabine can target Hedgehog signaling pathway to inhibit myelodysplastic syndrome cell line

References

• Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383(14):1358–1374. doi:https://doi.org/10.1056/NEJMra1904794.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Stone RM, Al-Kali A, et al. Myelodysplastic Syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(1):60–87. doi:https://doi.org/10.6004/jnccn.2017.0007.
   PubMed Web of Science ®Google Scholar
• Joshi K, Zhang L, Breslin SJP, et al. Advances in experimental medicine and biology. Adv Exp Med Biol. 2019;1143:95–128. doi:https://doi.org/10.1007/978-981-13-7342-8_5.
   PubMedGoogle Scholar
• Komrokji RS. Treatment of higher-risk myelodysplastic syndromes after failure of Hypomethylating agents. Clin Lymphoma Myeloma Leuk. 2015;15 Suppl:S56–S59. doi:https://doi.org/10.1016/j.clml.2015.03.010.
   PubMed Web of Science ®Google Scholar
• Flotho C, Sommer S, Lübbert M. DNA-Hypomethylating agents as Epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and Juvenile Myelomonocytic Leukemia. Semin Cancer Biol. 2018;51:68–79. doi:https://doi.org/10.1016/j.semcancer.2017.10.011.
   PubMed Web of Science ®Google Scholar
• Prébet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after Azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322–3327. doi:https://doi.org/10.1200/JCO.2011.35.8135.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Do I-G, Lee J, et al. Gastric Cancer (GC) patients with Hedgehog Pathway activation: PTCH1 and GLI2 as independent prognostic factors. Target Oncol. 2013;8(4):271–280. doi:https://doi.org/10.1007/s11523-013-0253-1.
   PubMed Web of Science ®Google Scholar
• Li H, Yue D, Jin JQ, et al. Gli promotes Epithelial-Mesenchymal Transition in human lung adenocarcinomas. Oncotarget. 2016;7(49):80415–80425. doi:https://doi.org/10.18632/oncotarget.11246.
   PubMedGoogle Scholar
• Terao T, Minami Y. Targeting Hedgehog (Hh) pathway for the Acute Myeloid Leukemia treatment. Cells. 2019;8(4):312, doi:https://doi.org/10.3390/cells8040312.
   PubMed Web of Science ®Google Scholar
• Qin Y, Jiang M, Tuerxung N, et al. Sonic Hedgehog signaling pathway in myelodysplastic Syndrome: Abnormal activation and Jervine intervention. Gene. 2020;754:144881, doi:https://doi.org/10.1016/j.gene.2020.144881.
   PubMedGoogle Scholar
• Zou J, Hong Y, Tong Y, et al. Sonic Hedgehog produced by Bone Marrow-Derived Mesenchymal stromal cells supports cell survival in myelodysplastic syndrome. Stem Cells Int 2015. 2015: 957502, doi:https://doi.org/10.1155/2015/957502.
   Google Scholar
• Xavier-Ferrucio JM, Pericole FV, Lopes MR, et al. Abnormal Hedgehog pathway in myelodysplastic syndrome and Its impact on Patients’ outcome. Haematologica. 2015;100(12):e491–e493. doi:https://doi.org/10.3324/haematol.2015.124040.
   PubMedGoogle Scholar
• Szeliga M, Ciura J, Tyrka M. Representational difference analysis of transcripts involved in Jervine biosynthesis. Life (Basel). 2020;10; doi:https://doi.org/10.3390/life10060088.
   Google Scholar
• Irvine DA, Copland M. Targeting Hedgehog in hematologic malignancy. Blood. 2012;119(10):2196–2204. doi:https://doi.org/10.1182/blood-2011-10-383752.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Glasdegib: first global approval. Drugs. 2019;79(2):207–213. doi:https://doi.org/10.1007/s40265-018-1047-7.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose Cytarabine with or without Glasdegib in patients with newly diagnosed Acute Myeloid Leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33(2):379–389. doi:https://doi.org/10.1038/s41375-018-0312-9.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Schuster MW, Krauter J, et al. Clinical benefit of Glasdegib in combination with Azacitidine or low-dose Cytarabine in patients with Acute Myeloid Leukemia. Blood. 2019;134:3916–3916. doi:https://doi.org/10.1182/blood-2019-124034.
   Google Scholar
• Zou J, Zhou Z, Wan L, et al. Targeting the Sonic Hedgehog-Gli1 pathway as a potential new therapeutic strategy for myelodysplastic syndromes. PLoS One. 2015;10:e0136843, doi:https://doi.org/10.1371/journal.pone.0136843.
   PubMed Web of Science ®Google Scholar
• Rimkus TK, Carpenter RL, Qasem S, et al. Targeting the Sonic Hedgehog signaling pathway: review of Smoothened and GLI inhibitors. Cancers. 2016;8(2):22, doi:https://doi.org/10.3390/cancers8020022.
   PubMedGoogle Scholar
• Will B, Zhou L, Vogler TO, et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and Epigenetic alterations. Blood. 2012;120(10):2076–2086. doi:https://doi.org/10.1182/blood-2011-12-399683.
   PubMed Web of Science ®Google Scholar
• Khan H, Vale C, Bhagat T, et al. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. Semin Hematol. 2013;50(1):16–37. doi:https://doi.org/10.1053/j.seminhematol.2013.01.001.
   PubMed Web of Science ®Google Scholar
• Hackanson B, Daskalakis M. Decitabine. Recent Results Cancer Res. 2014;201:269–297. doi:https://doi.org/10.1007/978-3-642-54490-3_18.
   PubMedGoogle Scholar
• Ganetsky A. The Role of Decitabine for the treatment of Acute Myeloid leukemia. Ann Pharmacother. 2012;46(11):1511–1517. doi:https://doi.org/10.1345/aph.1R151.
   PubMedGoogle Scholar
• Li Z, Mao S, Jin J. Activation of Hedgehog pathway in Acute Myeloid Leukemia patients. Int J Clin Exp Pathol. 2017;10:8605–8609.
   PubMed Web of Science ®Google Scholar
• Merchant AA, Matsui W. Targeting hedgehog–a Cancer stem cell pathway. Clin Cancer Res. 2010;16(12):3130–3140. doi:https://doi.org/10.1158/1078-0432.CCR-09-2846.
   PubMed Web of Science ®Google Scholar
• Tibes R, Al-Kali A, Oliver GR, et al. The Hedgehog pathway as targetable vulnerability with 5-Azacytidine in myelodysplastic syndrome and Acute Myeloid Leukemia. J Hematol Oncol. 2015;8(1):114, doi:https://doi.org/10.1186/s13045-015-0211-8.
   PubMedGoogle Scholar
• Jabbour E, Kantarjian HM, Garcia-Manero G, et al. Decitabine in myelodysplastic syndromes. Therapy. 2005;2:835–842. doi:https://doi.org/10.2217/14750708.2.6.835.
   Google Scholar
• Atallah E, Kantarjian H, Garcia-Manero G. The role of Decitabine in the treatment of myelodysplastic syndromes. Expert Opin Pharmacother. 2007;8(1):65–73. doi:https://doi.org/10.1517/14656566.8.1.65.
   PubMed Web of Science ®Google Scholar
• Ma Y-Y, Zhao M, Liu Y, et al. Use of decitabine for patients with refractory or relapsed Acute Myeloid Leukemia: A systematic review and meta-analysis. Hematology. 2019;24(1):507–515. doi:https://doi.org/10.1080/16078454.2019.1632407.
   PubMed Web of Science ®Google Scholar
• Mao J, Li S, Zhao H, et al. Effects of chidamide and Its combination with decitabine on proliferation and apoptosis of Leukemia cell lines. Am J Transl Res. 2018;10:2567–2578.
   PubMed Web of Science ®Google Scholar
• Dey N, De P, Leyland-Jones B. PI3K-AKT-MTOR inhibitors in breast cancers: from tumor cell signaling to clinical trials. Pharmacol Ther. 2017;175:91–106. doi:https://doi.org/10.1016/j.pharmthera.2017.02.037.
   PubMed Web of Science ®Google Scholar
• Lin S, Li J, Zhou W, et al. BIIB021, an Hsp90 inhibitor, effectively kills a myelodysplastic syndrome Cell Line via the activation of caspases and inhibition of PI3K/Akt and NF-ΚB pathway proteins. Exp Ther Med. 2014;7:1539–1544. doi:https://doi.org/10.3892/etm.2014.1651.
   PubMedGoogle Scholar
• Yin J, Li X, Zhang Z, et al. SPAG6 silencing induces apoptosis in the myelodysplastic syndrome Cell Line SKM-1 via the PTEN/PI3 K/AKT signaling pathway in vitro and in vivo. Int J Oncol. 2018;53:297–306. doi:https://doi.org/10.3892/ijo.2018.4390.
   PubMed Web of Science ®Google Scholar
• Riobó NA, Lu K, Ai X, et al. Phosphoinositide 3-Kinase and Akt are essential for Sonic Hedgehog signaling. Proc Natl Acad Sci U S A. 2006;103(12):4505–4510. doi:https://doi.org/10.1073/pnas.0504337103.
   PubMed Web of Science ®Google Scholar
• Yoo YA, Kang MH, Lee HJ, et al. Sonic Hedgehog pathway Promotes Metastasis and Lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in Gastric cancer. Cancer Res. 2011;71(22):7061–7070. doi:https://doi.org/10.1158/0008-5472.CAN-11-1338.
   PubMed Web of Science ®Google Scholar
• Ke Z, Caiping S, Qing Z, et al. Sonic Hedgehog-Gli1 signals promote Epithelial-Mesenchymal Transition in ovarian Cancer by mediating PI3K/AKT pathway. Med Oncol. 2015;32:368. doi:https://doi.org/10.1007/s12032-014-0368-y.
   PubMed Web of Science ®Google Scholar